Isracann Biosciences Financials
We strongly advise to harness Isracann Biosciences fundamental analysis to find out if markets are presently mispricing the company. Simply put you can make use of it to find out if Isracann Biosciences is indeed mispriced or if you can make any profits on it by purchasing it and then waiting for the market to recognize its mistake and reprise the security. We were able to interpolate twenty-two available reported financial drivers for Isracann Biosciences, which can be compared to its competitors.
Isracann |
Understanding current and past Isracann Biosciences Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Isracann Biosciences' financial statements are interrelated, with each one affecting the others. For example, an increase in Isracann Biosciences' assets may result in an increase in income on the income statement.
Isracann Biosciences Stock Summary
Isracann Biosciences Inc., together with its subsidiaries, cultivates and distributes medical cannabis in Israel. Isracann Biosciences Inc. was founded in 2010 and is headquartered in Vancouver, Canada. Isracann Biosciences is traded on OTC Exchange in the United States.| Instrument | USA Pink Sheet View All |
| Exchange | PINK Exchange |
| ISIN | CA46501D1087 |
| Business Address | 595 Burrard Street, |
| Sector | Healthcare |
| Industry | Drug Manufacturers—Specialty & Generic |
| Benchmark | Dow Jones Industrial |
| Website | www.isracann.com |
| Phone | 604 394 2551 |
| Currency | USD - US Dollar |
Isracann Biosciences Key Financial Ratios
There are many critical financial ratios that Isracann Biosciences' investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Isracann Biosciences reports annually and quarterly.| Return On Equity | -2.53 | |||
| Return On Asset | -0.35 | |||
| Beta | 0.12 | |||
| Z Score | -3.3 |
Isracann Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Isracann Biosciences's current stock value. Our valuation model uses many indicators to compare Isracann Biosciences value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Isracann Biosciences competition to find correlations between indicators driving Isracann Biosciences's intrinsic value. More Info.Isracann Biosciences is rated fourth overall in return on equity category among its peers. It also is rated fourth overall in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Isracann Biosciences' earnings, one of the primary drivers of an investment's value.Isracann Biosciences Systematic Risk
Isracann Biosciences' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Isracann Biosciences volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourteen with a total number of output elements of fourty-seven. The Beta measures systematic risk based on how returns on Isracann Biosciences correlated with the market. If Beta is less than 0 Isracann Biosciences generally moves in the opposite direction as compared to the market. If Isracann Biosciences Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Isracann Biosciences is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Isracann Biosciences is generally in the same direction as the market. If Beta > 1 Isracann Biosciences moves generally in the same direction as, but more than the movement of the benchmark.
Complementary Tools for Isracann Pink Sheet analysis
When running Isracann Biosciences' price analysis, check to measure Isracann Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Isracann Biosciences is operating at the current time. Most of Isracann Biosciences' value examination focuses on studying past and present price action to predict the probability of Isracann Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Isracann Biosciences' price. Additionally, you may evaluate how the addition of Isracann Biosciences to your portfolios can decrease your overall portfolio volatility.
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |